OPKO Health, Inc. has entered into an asset purchase agreement that requires compliance with a second request under the HSR Act.
SEC EDGAR, 2026-10-15: 8-K (Item 1.01, 9.01) — "second request", "consent order"
OPKO Health, Inc. has entered into an asset purchase agreement that requires compliance with a second request under the HSR Act.
Company: OPKO HEALTH, INC. (OPK) Filed: 2026-10-15, 8-K (Item 1.01, 9.01) Phrase: "second request" — "respond as promptly as practicable to any request from any Governmental Authority for information, documents or other materials in connection with the transactions contemplated hereby, including substantial compliance with any second request issued pursuant to the HSR Act;" What the filing says: OPKO Health, Inc. (as Seller Parent) and BioReference Health, LLC (as Seller) have entered into an Asset Purchase Agreement dated October 14, 2026, with Laboratory Corporation of America Holdings (as Buyer). The agreement is for the sale of OPKO's clinical and anatomic pathology laboratory testing business, including the 4Kscore Test. The filing states that both parties must use commercially reasonable efforts to respond to requests from governmental authorities, including substantial compliance with any second request issued pursuant to the HSR Act, which is part of the regulatory approval process for mergers and acquisitions. Two ways it goes: A. The antitrust review is completed, and the transaction closes as planned. B. The antitrust review leads to a challenge or blockage of the transaction. Next date: none named Watch: Announcement of the completion or outcome of the antitrust review.